City of Hope is a hub of innovation and progress when it comes to treating brain tumors. Our research and clinical teams work together to advance therapies that more effectively — and directly — target brain tumors. A groundbreaking case study conducted at City of Hope, and published in the New England Journal of Medicine, found that using CAR T cell therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma. And we are researching immunotherapy as a way of disabling cancer cells and finding unique ways to allow cancer drugs to cross the blood-brain barrier.

 

We are world leaders in the field of neural stem cell therapy, a groundbreaking method of delivering chemotherapy drugs directly to tumor sites within the brain — and were the first in the world to apply this exciting breakthrough therapy to brain cancer.

 

For more information about the brain tumor studies listed below, visit City of Hope's clinical trials website. If you have a newly developed or recurrent brain tumor and are interested in learning about our clinical trials or referring a patient for enrollment, please email neurosurgerymail@coh.org.

NCT04471844: We are recruiting patients to participate in this Phase 3 study, a multicenter study to test the effectiveness and safety of Optune given concomitantly with radiation therapy and temozolomide in newly diagnosed glioblastoma patients.

Patient Enrollment Qualifications

• Age 18 years or older
• Patients newly diagnosed with glioblastoma

Recurrent High-Grade Gliomas

NCT05218408: We are recruiting patients to participate in a trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin-2 in adults with recurrent resection-eligible IDH1 wild-type glioblastoma.

Patient Enrollment Qualifications

• Age 18 years or older
• Glioblastoma patients at first or second recurrence

_______________________

NCT05139056: Patients with recurrent high-grade gliomas will soon have the opportunity to participate in a study to assess the safety and effectiveness of multiple doses of neural stem cells in combination with an oncolytic virus.

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with recurrent high-grade glioma

_______________________

NCT05139043: We are recruiting patients to study whether low-dose dexamethasone works as well as standard-dose dexamethasone to reduce brain swelling after brain surgery in patients with primary brain tumors or cancer that has spread from other places in the body to the brain (metastatic).

Patient Enrollment Qualifications

• Age 18 years or older
• Patients with primary or metastatic brain tumors who need surgery to remove the tumor

_______________________

NCT04214392: We're recruiting for a study on the possible benefits and optimal doses of CAR T cells with a chlorotoxin tumor-targeting domain to treat MMP2+ recurrent high-grade gliomas.

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with recurrent high-grade glioma

_______________________

NCT03389230: If you've been diagnosed with recurrent high-grade gliomas, you may be eligible to participate in a study using memory-enriched T cells — specifically, HER2 (EQ) BBᶳ/CD19 t+ T cells aimed at killing glioma tumor cells.

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with recurrent high-grade glioma

_______________________

NCT04003649: We're recruiting patients for a study that combines two types of immunotherapy using CAR T cells together with nivolumab and/or ipilimumab.

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with recurrent high-grade glioma

_______________________

NCT04661384: Patients with leptomeningeal disease may be eligible to participate in a study of CAR T cell therapy to assess the benefits of treatment using brain tumor-specific immune cells.

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with leptomeningeal metastases from glioblastoma, ependymoma or medulloblastoma

Learn more about this promising study

_______________________

NCT04510051: Children or young adults with recurrent malignant primary brain tumors can participate in a study to assess the safety and best dose of CAR T cell therapy.

Patient Enrollment Qualifications

• Age 4 to 25 years old
• Recurrent malignant primary brain tumors

_______________________

NCT05267106: This is a multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated glioblastoma or other primary central nervous system tumors harboring activating FGFR1-3 alterations (FIGHT-209).

Patient Enrollment Qualifications

• Age 18 years or older
• Diagnosed with recurrent glioblastoma or other primary CNS tumors that have an FGFR 1-3 alteration